| Cell line name | haNK GFP |
|---|---|
| Synonyms | GFP haNK; GFP+CD16-V158.NK-92.05 |
| Accession | CVCL_VN53 |
| Resource Identification Initiative | To cite this cell line use: haNK GFP (RRID:CVCL_VN53) |
| Comments | Population: Caucasian. Characteristics: No longer dependent on IL2. Transfected with: HGNC; 3619; FCGR3A (with p.Phe176Val). Transfected with: HGNC; 6001; IL2. Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers for this cell line. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support. Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178. Cell type: Natural killer cell; CL=CL_0000623. |
| Disease | Natural killer cell lymphoblastic leukemia/lymphoma (NCIt: C82217) |
| Species of origin | Homo sapiens (Human) (NCBI Taxonomy: 9606) |
| Hierarchy | Parent: CVCL_IM23 (haNK) |
| Sex of cell | Male |
| Age at sampling | 50Y |
| Category | Cancer cell line |
| Web pages | https://brinkbiologics.com/platform/ |
| Cross-references | |
| Encyclopedic resources | Wikidata; Q93938283 |
| Entry history | |
| Entry creation | 07-Sep-2018 |
| Last entry update | 05-Oct-2023 |
| Version number | 6 |